Dysregulated mature IL-1β production in familial Mediterranean fever

Rheumatology (United Kingdom)

Volumn 54, Issue 4, 2014, Pages 660-665

  Migita, Kiyoshi ^a   Izumi, Yasumori ^a   Fujikawa, Keita ^b   Agematsu, Kazunaga ^c   Masumoto, Junya ^d   Jiuchi, Yuka ^a   Kozuru, Hideko ^a   Nonaka, Fumiaki ^e   Shimizu, Toshimasa ^e   Nakamura, Tadashi ^f   Iwanaga, Nozomi ^a   Furukawa, Hiroshi ^g   Yasunami, Michio ^h   Kawakami, Atsushi ⁱ   Eguchi, Katsumi ^e  

^a NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^b Isahaya Health Insurance General Hospital   (Japan)

^c SHINSHU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e Sasebo Shiritsu Sogo Hospital   (Japan)

^f Kumamoto Shinto General Hospital   (Japan)

^g NATIONAL HOSPITAL ORGANIZATION   (Japan)

^h NAGASAKI UNIVERSITY   (Japan)

ⁱ NAGASAKI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Autoinflammatory disease; Biomarker; Familial mediterranean fever; IL 1 ; Serum amyloid A

Indexed keywords

COLCHICINE; INTERLEUKIN 1BETA; SERUM AMYLOID A;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILIAL MEDITERRANEAN FEVER; FEMALE; HUMAN; IMMUNOBLOTTING; MALE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; REMISSION; TREATMENT OUTCOME; TREATMENT RESPONSE; WESTERN BLOTTING;

EID: 84926479108     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu359     Document Type: Article

References (19)

1. Savic S, Dickie LJ, Battellino M, McDermott MF. Familial Mediterranean fever and related periodic fever syndromes/autoinflammatory diseases. Curr Opin Rheumatol 2012;24:103-12.
2. Samuels J, Aksentijevich I, Torosyan Y et al. Familial Mediterranean fever at the millennium. Clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health. Medicine 1998;77: 268-97.
3. Hashkes PJ, Spalding SJ, Giannini EH et al. Rilonacept for colchicine-resistant or-intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med 2012;157: 533-41.
4. Omenetti A, Carta S, Delfino L et al. Increased NLRP3-dependent interleukin 1b secretion in patients with familial Mediterranean fever: correlation with MEFV genotype. Ann Rheum Dis 2014;73:462-9.
5. Ben-Zvi I, Livneh A. Chronic inflammation in FMF: markers, risk factors, outcomes and therapy. Nat Rev Rheumatol 2011;7:105-12.
6. Chae JJ, Aksentijevich I, Kastner DL. Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy. Br J Haematol 2009;146: 467-78.
7. Dinarello CA. Blocking IL-1 in systemic inflammation. J Exp Med 2005;201:1355-9.
8. Dinarello CA. IL-1: discoveries, controversies and future directions. Eur J Immunol 2010;40:599-606.
9. Allantaz F, Chaussabel D, Banchereau J, Pascual V. Microarray-based identification of novel biomarkers in IL-1-mediated diseases. Curr Opin Immunol 2007;19: 623-32.
10. Livneh A, Langevitz P, Zemer D et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 1997;40:1879-85.
11. Borth W, Scheer B, Urbansky A, Luger TA, Sottrup-Jensen L. Binding of IL-1 beta to alpha-macroglobulins and release by thioredoxin. J Immunol 1990;145: 3747-54.
12. Borth W, Urbanski A, Prohaska R, Susanj M, Luger TA. Binding of recombinant interleukin-1 beta to the third complement component and alpha 2-macroglobulin after activation of serum by immune complexes. Blood 1990; 75:2388-95.
13. Soriano A, Verecchia E, Afeltra A, Landolfi R, Manna R. IL-1b biological treatment of familial Mediterranean fever. Clin Rev Allergy Immunol 2013;45:117-30.
14. Simsek I, Pay S, Pekel A et al. Serum proinflammatory cytokines directing T helper 1 polarization in patients with familial Mediterranean fever. Rheumatol Int 2007;27: 807-11.
15. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;87:2095-147.
16. Chae JJ, Wood G, Richard K et al. The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-kappaB through its N-terminal fragment. Blood 2008;112:1794-803.
17. Chae JJ, Wood G, Masters SL et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1b production. Proc Natl Acad Sci USA 2006;103:9982-7.
18. Papin S, Cuenin S, Agostini L et al. The SPRY domain of pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1b processing. Cell Death Differ 2007;14: 1457-66.
19. Chae JJ, Cho YH, Lee GS et al. Gain-of-function pyrin mutations induce NLRP3 protein-independent interleukin-1b activation and severe autoinflammation in mice. Immunity 2011;34:755-68.